SAN FRANCISCO--(BUSINESS WIRE)--Today, Exavir Therapeutics announced that the company has entered into a settlement and license agreement with ViiV Healthcare for ultra-long-acting HIV compounds. As part of the agreement, Exavir will receive an upfront and milestone payments, as well as low-to-mid single digit royalties on future sales..

旧金山--（商业新闻短讯）--今天，Exavir Therapeutics宣布，该公司已与ViiV Healthcare就超长效HIV化合物达成和解和许可协议。作为协议的一部分，Exavir将获得预付款和里程碑付款，以及未来销售的中低个位数版税。。

Exavir Therapeutics is focused on discovering and developing ultra-long-acting therapeutics with best-in-class product profiles. The company uses its proprietary prodrug and formulation technology to develop novel extended half-life therapeutics with potential for dosing as infrequent as once-every-six-months or even once-a-year..

Exavir Therapeutics专注于发现和开发具有一流产品概况的超长效疗法。该公司使用其专有的前药和配方技术开发新型延长半衰期疗法，其给药频率可能不高，每六个月甚至一年一次。。

“We are excited to reach an agreement with the scientific and market leader in long-acting injectables for HIV. We look forward to the continued success of ViiV Healthcare in their efforts to discover and develop more convenient and effective therapies for people living with HIV or at risk of acquiring HIV,” said Alborz Yazdi, co-founder and CEO of Exavir..

Exavir联合创始人兼首席执行官阿尔博兹·亚兹迪（Alborz Yazdi）表示：“我们很高兴能与艾滋病毒长效注射剂的科学和市场领导者达成协议。我们期待着ViiV Healthcare在为艾滋病毒感染者或有感染艾滋病毒风险的人发现和开发更方便有效的疗法方面取得持续成功。”。。